Shattuck Labs (STTK) Current Deferred Revenue (2019 - 2024)
Shattuck Labs (STTK) posted quarterly Current Deferred Revenue of $3.0 million for Q2 2024, down 34.93% quarter-over-quarter from $4.6 million in Q1 2024.
Analysis
Shattuck Labs (STTK) Current Deferred Revenue (2019 - 2024) Analysis & Trends
Shattuck Labs (STTK) has reported Current Deferred Revenue for 5 consecutive years, with $3.0 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Current Deferred Revenue changed N/A year-over-year to $3.0 million; the TTM figure through Jun 2024 stood at $3.0 million (changed N/A YoY), while the FY2023 annual figure was $343000.0, changed N/A from the prior year.
- Current Deferred Revenue retreated to $3.0 million in Q2 2024 per STTK's latest filing, from $4.6 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $9.7 million in Q1 2021 and bottomed at $343000.0 in Q4 2023.
- Historically, Current Deferred Revenue has averaged $4.9 million across 4 years, with a median of $3.8 million in 2024.
- Annual changes were most pronounced in 2020 — Current Deferred Revenue plunged 40.07% — and 2021, when it sank 67.48%.
- Shattuck Labs' Current Deferred Revenue stood at $7.7 million in 2020, then plunged by 63.76% to $2.8 million in 2021, then tumbled by 87.75% to $343000.0 in 2023, then jumped by 773.76% to $3.0 million in 2024.
- Business Quant data shows STTK's Current Deferred Revenue at $3.0 million in Q2 2024, $4.6 million in Q1 2024, and $343000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Shattuck Labs | 885.09 Mn | 885.09 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 3.00 Mn |
| Mar 31, 2024 | 4.61 Mn |
| Dec 31, 2023 | 343,000.00 |
| Sep 30, 2021 | 2.80 Mn |
| Jun 30, 2021 | 2.78 Mn |
| Mar 31, 2021 | 9.66 Mn |
| Dec 31, 2020 | 7.73 Mn |
| Sep 30, 2020 | 8.61 Mn |
| Dec 31, 2019 | 12.89 Mn |